Rayonier Advanced Materials Inc

Rayonier Advanced Materials Inc has a market price of $8.61 and a market capitalization of $580.26 million, with a price-to-book ratio of 1.83 and a price-to-tangible-book ratio of 1.83. The company's enterprise value to EBITDA ratio is 321.61, indicating a high valuation relative to its earnings, while the enterprise value to revenue ratio is 0.88, suggesting a relatively low valuation in terms of revenue. The company's liquidity position is characterized by a current ratio of 1.58 and a debt-to-equity ratio of 2.46, indicating a moderate level of leverage. The company's profitability is weak, with a return on equity of -1.33 and a return on assets of -0.24, both significantly below industry norms. The operating income of $3.99 million is a small fraction of the company's revenue of $1.47 billion, and the net income is negative at -$420.67 million, indicating substantial losses. The gross profit of $118.79 million is also relatively low compared to the company's revenue, suggesting high production costs or low pricing power. Rayonier Advanced Materials Inc's revenue is primarily derived from its specialty chemicals business, with a significant portion coming from the North American market. The company's geographic exposure is concentrated, with a large portion of its revenue generated in the United States. The company's segment performance is not disclosed in detail, but the overall financial performance indicates challenges in maintaining profitability. The company's growth trajectory is mixed, with a free cash flow of -$399.95 million and a capital expenditure of -$115.60 million, indicating significant cash outflows. The operating cash flow of $23.91 million is positive but insufficient to cover the capital expenditures, suggesting a need for external financing. The company's liquidity risk is medium, and the dilution risk is low, but the net cash position is negative after subtracting total debt. Recent events and filings indicate that the company is facing financial challenges, with a net loss of $420.67 million and a negative return on equity. The company's financial performance has raised concerns among analysts, with a mean price target of $14.50 and a mean recommendation of 2.00, indicating a neutral outlook. The company's financial health is further complicated by its high debt levels and negative net income. The company's risk assessment highlights a medium liquidity risk and a low dilution risk, but the net cash position is negative after subtracting total debt. The company's financial performance and risk profile suggest that it is facing significant challenges in maintaining profitability and liquidity. The company's capital structure and financial performance indicate a need for strategic adjustments to improve its financial health.